SOTAX Corporation BioJECT Cell
"We will exhibit at the Pharma Lab EXPO Tokyo" - New solution for subcutaneous injection drug release testing - BioJECT Cell
We are pleased to announce that SOTAX, in close collaboration with the National University of Singapore, has developed a new BioJECT cell (patent pending) compatible with the CE7smart (SOTAX JP3 (USP4) flow-through cell dissolution testing device) as a new solution for in vitro testing of subcutaneous injection drugs such as insulin. This cell features a small container called a biomatrix for filling samples, allowing for testing that simulates subcutaneous tissue. By combining the BioJECT cell with the CE7smart, we support the development of effective testing methods for various subcutaneous injection drugs, including in-situ implants, peptides, and low molecular weight compounds. ■ Exhibition Name: 7th Pharma Lab EXPO Tokyo ■ Dates: July 9 (Wed) - 11 (Fri), 2025 ■ Time: 10:00 AM - 5:00 PM ■ Venue: Tokyo Big Sight ■ Booth Number: E6-26
- Company:DKSHマーケットエクスパンションサービスジャパン テクノロジー事業部門
- Price:Other